You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NEWS / EVENTS / .........

EVENTS - 26-07-2016

SIPPET Study was WHF 2016 World Congress highlight

The 2016 World Congress of the World Federation of Hemophilia took place in Orlando, Florida from 24 to 28 July 2016. After many years, the World Congress returned to US soil; and a turnout of about 8000 people has been registered. As World Congress Supporter, Kedrion Biopharma was present with a booth and with a large delegation of international guests coming from Italy, Turkey, Serbia and Latin America.

The WFH Congress is a biannual event that is deeply appreciated by the global hemophiliac community because it is the most important event that is open to patients. Information shared in the different sessions is especially tailored to reach and to educate the community of the patients and their families.

Given the clinical repercussions that its results are already manifesting, it was expected that the SIPPET study would play a key role also during the WFH Congress. This undoubtedly was the case. Kedrion along with Grifols and LFB organized a symposium on SIPPET for 25 July entitled “New insights on inhibitor development: implications for PUPs management”; the symposium featured a lecture by Dr. Manuel Carcao, Director of the Hemophilia Clinic at the Hospital for Sick Children in Toronto, Canada and a final round table, chaired by Dr. Louis Aledort and Dr. Guy Young, with a debate between clinical experts and patient associations from around the world.

For more information please contact: